tiprankstipranks
The Fly

Editas Medicine downgraded to Hold from Buy at Stifel

Editas Medicine downgraded to Hold from Buy at Stifel

Stifel downgraded Editas Medicine (EDIT) to Hold from Buy with a price target of $3, down from $11. The company’s previously stated intentions to switch to in vivo editing “still left some hope” that reni-cel for sickle cell disease had a path forward, but the company’s decision to end development “after extensive search did not yield a commercial partner” is “disappointing,” the analyst tells investors. With reni-cel removed and a preclinical asset left to drive Editas’ valuation, the path forward “looks long and challenging,” the analyst added.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

1